Abstract
Background
Herein, a 3-year-old boy presented with hidden-onset isolated proteinuria was reported. The disease was induced by COQ8B (previously termed ADCK4) compound heterozygous variants, including c.[271C > T] and c.[737G > A], which were inherited from his father and mother, respectively.
Case presentation
The patient visited our clinic due to non-nephrotic range proteinuria for 3 months, but no obvious abnormality was detected in the vital signs or laboratory test results. Renal histopathology revealed mitochondrial nephropathy, which manifested as mild glomerular abnormalities under light microscope, together with mitochondrial proliferation and hypertrophy and crowded arrangement under electron microscope. As suggested by whole exome sequencing, the patient inherited the COQ8B compound heterozygous variants from both of his parents who showed normal phenotype. After literature review, it was confirmed that one of the variant site (c.[271C > T]) had not been reported among the East Asian populations so far.
Conclusions
Steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis are the most common phenotypes and renal histopathological manifestations of COQ8B variant. Nonetheless, our case shows that such variant may have hidden and mild clinical manifestations at the early onset. Therefore, early diagnosis will help to identify children at the early disease stage who have opportunity to benefit from oral coenzyme Q10 supplementation.
Keywords: Isolated proteinuria, Child, COQ8B (ADCK4) Glomerulopathy, CoQ10
Background
Proteinuria is one of the most common causes that prompt children and adolescents to visit a pediatric nephrologist. As reported by one study involving 37,645 children, 2.3% children have developed persistent proteinuria [1]. Transient or orthostatic proteinuria is usually benign, while persistent proteinuria may represent an early renal disease [2]. In fact, proteinuria is an independent risk factor that induces renal disease progression [3]. However, under numerous circumstances, proteinuria fails to arouse enough attention, and no accurate treatment is applied until it comes to end-stage renal disease (ESRD). In this paper, a child presented with isolated proteinuria was reported, and his renal histopathology showed mitochondrial nephropathy. Upon examinations, the disease was identified to be induced by the compound heterozygous variants in COQ8B (ADCK4) gene, and the patient was diagnosed with ADCK4-associated glomerulopathy (ADCK4-GN).
ADCK4-GN is an autosomal recessive chronic kidney disease, which can be induced by allelic homogeneous variant or compound heterozygous variants of ADCK4 gene [4]. Patients with ADCK4-GN mainly manifest as steroid-resistant nephrotic syndrome (SRNS) [5], and their renal histopathology mostly manifest as focal segmental glomerulosclerosis (FSGS) [6]. Although the morbidity of ADCK4-GN remains unclear so far, ADCK4 variant has accounted for the most common monogenic disorder among the SRNS patients in China [7, 8].
Considering the hidden onset, rapid progression and poor prognosis of the disease, especially with ESRD as the outcome, early diagnosis plays an essential role in terminating disease progression by Coenzyme Q10 (CoQ10) supplementation at the early stage [9].
Case presentation
A 3-year-old boy was admitted to our hospital due to isolated proteinuria for 3 months. The patient did not receive routine urine test until he got pharyngitis. Notably, the quantity of proteinuria once reached the nephrotic range (0.93 g/24 h, 53 mg/kg), which then decreased to between 0.59 g/24 h and 0.62 g/24 h after the recovery of infection. During the entire course of disease, there was no edema. The patient was treated with Chinese herbal medicines at the local hospital although no definite diagnosis was made. However, proteinuria was not improved after nearly 3 months of treatment.
Both of his parents were healthy and provided normal results in routine urine test. In addition, they denied any positive family history of nephropathy. No obvious abnormality was detected in the prenatal examinations, and his vital signs and systematic physical examinations were normal. The total quantity of proteinuria was within the non-nephrotic range (590 mg/24 h, 33 mg/kg), which was dominated by albuminuria (522.90 mg/24 h). Besides, there was no abnormality in the low molecular weight proteinuria (LMWP) or the urine calcium-to-creatinine ratio, with no hematuria. Laboratory investigations revealed mild hypoalbuminemia (35.7 g/L), no hypercholesterolemia (4.52 mmol/L) and normal glomerular filtration rate (eGFR, 189.54 ml/min). Moreover, the patient did not have any significant illnesses, including hepatitis B, tuberculosis, IgA vasculitis or systemic lupus erythematosus. Besides, both ASO and EBV-IgM were negative. Renal ultrasound revealed normal echogenicity (left kidney, 72 mm × 32 mm, right kidney, 68 mm × 27 mm).
Clinically, the patient presented with isolated proteinuria, which was identified as glomerular proteinuria, while both the low molecular weight proteinuria and urine calcium-to-creatinine ratio were normal. Therefore, renal tubular diseases, such as Dent disease, were ruled out. Furthermore, there was no evident evidence of nephrotic syndrome since the patient had neither nephrotic proteinuria nor hypercholesterolemia, regardless of the mild hypoalbuminemia. Moreover, there was no evidence of secondary nephritis, including purpura nephritis, lupus nephritis or hepatitis B-related nephropathy. Based on the above findings, the patient was treated with angiotensin converting-enzyme inhibitor (ACEI) before renal biopsy, hoping to improve proteinuria.
Renal histopathology under light microscope (LM) showed that, one glomerulus turned sclerosis, while the other thirty one glomeruli exhibited minor glomerular abnormalities (Fig. 1b). Immunofluorescence was negative. Besides, electron microscope (EM) observation revealed mitochondrial proliferation and hypertrophy, as well as crowded arrangement in the lumen plane of renal tubules (Fig. 1d).
Fig. 1.
Renal histology of the patient. a Most glomeruli show no abnormality by PASM staining. b Among the 32 glomeruli, one reveals global glomerulosclerosis (white arrow heads). (PASM× 200). (Method: Light microscope: OLYMPUS, BX51. Image acquisition system: OLYMPUS, DP72.) (c) EM shows mild hyperplasia of mesangial cells and mesangial matrix. (× 10,000) (d) Proliferation and hypertrophy of mitochondria and crowded arrangement are observed on the lumen plane of renal tubules. (× 8000) (Method: Electron microscope: JEM1230, Japan JEOL Company. Camera: Model 832 digital image transmission instrument (CCD Camera), America Gatan Company)
As confirmed by Whole exome sequencing (WES) analysis, there were compound heterozygous variants in the COQ8B gene inherited from both of his parents. Of them, the variant (c.[271C > T]), which had not been reported among Asians, was inherited from his father (Fig. 2a) (According to GnomAD, this variant was presented in heterozygous state and detected in three individuals in Europeans. (https://gnomad.broadinstitute.org/variant/19-41219990-G-A?dataset=gnomad_r2_1.). Meanwhile, the missense variant (c.[737G > A]), which had been reported previously, was inherited from his mother (Fig. 2b). The pathogenicity of both variants was analyzed, as displayed in Table 1. The online Polyphen2 and SIFT software were used for the interpretation of the missense sequence variants. In silico (computational) prediction, these variants were predicted to be PROBABLY DAMAGING using the Polyphen2 tool (http://genetics.bwh.harvard.edu/pph2/). However, the prediction result was deleterious using SIFT tool (http://sift.jcvi.org). MAF of 0.00 for the c.[271C > T] variant was shown in population data, including dbSNP, 1000 Genomes Project, ExAC (East Asia), ExAC (South Asia), while in GnomAD, this variant was presented in heterozygous state and detected in three individuals in Europeans. MAF for the c.[737G > A] variant varied between different databases, as displayed in Table 1. According to ACMG, the pathogenicity of the sequence variant c.[271C > T] was of uncertain significance (PP3). The proband’s father with the same heterozygous variant had normal phenotype. Similarly, the pathogenicity of the sequence variant c.[737G > A] was also of uncertain significance (PP3), and his mother also showed normal phenotype. Notably, the sequence variant c.[271C > T] was located at exon 4, which coded the helical domain, whereas the sequence variant c.[737G > A] was located at exon 9 and coded the kinase domain. The amino acids encoded by the two above-mentioned sequence variants were of evolutionary conservation (Fig. 3). The variants in the proband were compound heterozygotes, which were consistent with the pathogenesis of autosomal recessive (AR) compound heterozygous genetic diseases. Moreover, the segregation of phenotypes and genotypes of the proband was consistent with that of his family members. Neither other nephrotic syndrome-related genes nor any copy number variations were detected. Mitochondrial detection also came to negative results. Combined with the typical renal histopathological findings, the diagnosis of ADCK4-GN was made, which was derived from the compound heterozygous sequence variants of the COQ8B(ADCK4) gene.
Fig. 2.
Genomic analysis. WES results of the patient and his parents indicate that our patient has 2 variants in the COQ8B gene: (a) c.[271C > T], p.(Arg91Cys), exon 4, chr19:41219990, inherited from his father; (b) c.[737G > A], p.(Ser246Asn), exon 9, chr19:41209508, inherited from his mother. Mitochondrial variants are not found
Table 1.
Genomic analysis
| Gene | Chr | Nucleic acid(Exon) | amino acid | RS | Pathogenicity (ACMG) | Proband | Father | Mother |
|---|---|---|---|---|---|---|---|---|
| COQ8B | chr19:41219990 | c.[271C > T](exon 4) | p.(Arg91Cys) | rs75497 5339 | Uncertain significance: PP3a | Het | Het | Wild type |
| chr19:41209508 | c.[737G > A](exon 9) | p.(Ser246Asn) | rs2008 41458 | Uncertain significance: PP3b | Het | Wild type | Het | |
| a(sift,Polyphen2_HDIV,Polyphen2_HVAR,PROVEAN,MutationTaster,M- CAP,REVEL,GERP,phyloP20way,phastCons20way) | ||||||||
| Population data | Computational and predictive data | |||||||
| Database | dbSNP | 1000 Genomes Project | ExAC (East Asia) | ExAC (South Asia) | GnomAD (East Asia) | Polyphen2 | SIFT | |
| MAF | Not included | Not included | 0.00 | 0.00 | 0.00 | PROBABLY DAMAGING | Deleterious | |
| b(sift,Polyphen2_HDIV,Polyphen2_HVAR,MutationTaster,M-CAP,GERP,phyloP20way,phastCons20way) | ||||||||
| Population data | Computational and predictive data | |||||||
| Database | dbSNP | 1000 Genomes Project | ExAC (East Asia) | ExAC (South Asia) | GnomAD (East Asia) | Polyphen2 | SIFT | |
| MAF | 0.000088 | 0.0024 | 0.0013 | 0.00 | 0.018 | PROBABLY DAMAGING | Deleterious | |
a(sift,Polyphen2_HDIV,Polyphen2_HVAR,PROVEAN,MutationTaster,M- CAP,REVEL,GERP,phyloP20way,phastCons20way)
b(sift,Polyphen2_HDIV,Polyphen2_HVAR,MutationTaster,M-CAP,GERP,phyloP20way,phastCons20way)
Fig. 3.
a Domain structure of ADCK4. The helical and kinase domains are depicted by colored bars in relation to encoding exon position. b Exon structure of human ADCK4 cDNA. ADCK4 contains 15 exons. c Variants of the ADCK4 gene. d Amino acid changes. e For the 2 missense variants conservation across evolution of altered amino acid residues is shown
Given the potential neurological involvement, further neurological system examinations were performed, including physical examinations and imaging examinations. The proband presented with neither hypotonia nor psychomotor delay. No abnormality was detected in brain magnetic resonance imaging (MRI) or electroencephalogram (EEG), and there was neither visual loss nor sensorineural hearing loss.
ACEI treatment was thus terminated, and the child was given treatment with CoQ10 (15 mg/kg·d) since then. Proteinuria and eGFR were persistently monitored, which showed that proteinuria gradually decreased during the 3-month-follow-up period (0.33 g/24 h, 18.9 mg/kg in the third month). In the fifth month, proteinuria decreased to 0.28 g/24 h, and eGFR was within the normal range.
Discussion and conclusions
ADCK4-GN is a disease related to mitochondrial dysfunction. Generally, mitochondrial dysfunction can be caused by variants in either mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) genes that encode proteins involved in the mitochondrial function [10]. It has been identified that, variants of COQ8B (ADCK4) gene can cause CoQ10 deficiency and mitochondrial nephropathy [11]. The affected patients may present with isolated renal diseases or accompanying extrarenal symptoms. For instance, one Japanese paper first reported a patient with Crohn’s disease (CD) combined with ADCK4-GN [12]. CoQ10, also known as the ubiquinone, is a vital part of the mitochondrial respiratory chain, which participates in the beta-oxidation of fatty acids and the synthesis of pyrimidine nucleoside; in addition, it serves as a cofactor for mitochondrial dehydrogenases [13]. CoQ10 is synthesized ubiquitously through the multienzyme complex on the inner mitochondrial membrane, in which at least 15 genes are involved [14] It seems that two genes have a regulatory role, including COQ8 (and its human counterparts COQ8A/ADCK3 and COQ8B/ADCK4) that encodes a putative kinase [15]. COQ8B interacts with the components in the CoQ10 biosynthesis pathway, and patients harboring COQ8B variants have reduced intracellular CoQ10 contents. Furthermore, it is reported that COQ8B is expressed in glomerular podocytes and partially localized in podocytic mitochondria as well as the podocytic processes in rat kidneys and cultured human podocytes [16]. Variants of COQ8B sequence participate in the effacement of podocytic process and the disorganization of filtration slit, which contributes to albuminuria and even nephrotic syndrome.
Variants in COQ8B sequence frequently cause SRNS with variable neurological involvement [17]. Typically, nephrotic syndrome constitutes the common etiology of proteinuria. About 10–20% pediatric patients with nephrotic syndrome do not achieve sustained remission after glucocorticoid therapy or additional immunosuppressive therapy, and finally progress into ESRD [18]. With the development of gene detection technology for pathogenic variants, genes that result in SRNS have attracted wide attention. Currently, at least 50 genes have been identified to lead to monogenic SRNS [19, 20]. A Chinese study [7] presents the spectrum of mutations among the Chinese children with SRNS, in which the most common mutated gene is COQ8B (ADCK4), followed by NPHS1, WT1, and NPHS2. Another recent Chinese cohort study investigates the genetic spectrum of renal disease among 1001 Chinese children based on the multicenter registration system. The results demonstrate that the mutation of COQ8B (ADCK4) gene is the major cause of SRNS [8]. The reported cases with COQ8B (ADCK4) are often diagnosed with SRNS, with FSGS as the renal histopathology [21], and such patients may even develop renal failure. Our patient clinically presented with isolated proteinuria without edema, along with normal renal function but not extrarenal symptoms. Typically, proteinuria may be of glomerular or tubulointerstitial origin [2]. For our case, tubulointerstitial proteinuria was first considered, because of his persistent proteinuria without edema. The 24-h urine protein excretion tests showed that albuminuria was dominant, with no low molecular weight proteinuria detected. Besides, his renal histopathology under EM showed mitochondrial nephropathy. Fortunately, the patient did not progress to FSGS. Using the WES technology, the COQ8B compound heterozygous variants were identified in the patient. COQ8B gene is located on human chromosome 19q13.2, which encodes the COQ8B protein. There are three functional regions in the COQ8B protein, including a helical domain, an ABC1 domain and a kinase domain, and it interacts with members of the CoQ10 biosynthesis pathway, including COQ6. The COQ8B compound heterozygous variants were identified in our patient, of which, the variant c.[271C > T] was inherited from his father, while c.[737G > A] was inherited from his mother. The amino acid residue 246 is located in the kinase domain, whereas the residue 91 is in the helical domain. The proteins affected by the above-mentioned sequence variants were conserved. Literature review was conducted to examine the phenotype and genotype of ADCK4 variants in children (Table 2), which suggested that allelic homogeneous variants or compound heterozygous variants of ADCK4 gene were the causes of disease. Similarly, the nephropathy of our proband was caused by the compound heterozygous variants of ADCK4 gene. Different from the reported SRNS and FSGS, our proband showed mild phenotype and renal histopathology.
Table 2.
Phenotype and genotype of CoQ8B(ADCK4) variants in children
| References | Family- individual | Nucleotide alteration | Amino acid change | Ethnic group | Phenotype | Renal histopatholgy | Treatment |
|---|---|---|---|---|---|---|---|
| Ashraf et al [11] (2013) | 1–1 |
c.101[G > A] (het) c.[954_956dup] (het) |
p.(Trp34*) p.(Thr319dup) |
European | SRNS | FSGS | PNL, tacrolimus, renal transplantation |
| 2–1 | c.[532C > T] (homo) | p.(Arg178Trp) | Arab | SRNS | GS | renal transplantation | |
| 2–2 | c.[532C > T] (homo) | p.(Arg178Trp) | Arab | SRNS | FSGS | renal transplantation | |
| 3–1 |
c.[645delT] (het) c.[1430G > A] (het) |
p.(Phe215Lfs*14) p.(Arg477Gln) |
Algerian Algerian |
SRNS | FSGS | renal transplantation | |
| 3–2 | SRNS | FSGS | renal transplantation | ||||
| 4–1 |
c.[857A > G] (het) c.[1447G > T] (het) |
p.(Asp286Gly) p.(Glu483*) |
ND (no data) | SRNS | FSGS | CsA, renal transplantation | |
| 4–2 | SRNS | FSGS | ND | ||||
| 4–3 | SRNS | FSGS | ACEI | ||||
| 5–1 | c.[958C > T] (homo) | p.(Arg320Trp) | Tunisian | SRNS | FSGS | ACEI, renal transplantation | |
| 5–2 | SRNS | ND | No treatment | ||||
| 6–1 | c.[1027C > T] (homo) | p.(Arg343Trp) | Moroccan | SRNS | ND | ND | |
| 6–2 | SRNS | FSGS | PNL | ||||
| 7–1 | c.[1199-1200insA] (homo) | p.(His400Nfs*11) | Turkish | SRNS | FSGS | PNL, ACEI, CP-R, CoQ10 | |
| 8–1 | c.[1356-1362del] (homo) | p.(Gln452Hfs) | Indian | SRNS | FSGS | CsA, ACEI | |
| 8–2 | SRNS | FSGS | ACEI | ||||
| Li et al [22] (2015) | 1–1 | c.[625C > G] (homo) | p.(Asp209His) | Chinese | Proteinuria | FSGS | CoQ10 |
| Korkmaz et al [21] (2016) | 26patients From 12families | c.[293 T > G] | p.(Leu98Arg) | Turkey | SRNS | FSGS | Immunosuppressive therapy; CoQ10 |
| c.[929C > T] | p.(Pro310Leu) | Turkey | SRNS | FSGS | |||
| c.[1493-1494CC > AA] | p.(Ala498Glu) | Turkey | SRNS | FSGS | |||
| c.[1339dupG] | p.(Glu447Glyfs*10) | Turkey | SRNS | FSGS | |||
| Wang et al [7] (2017) | 1–1 |
c.[241G > T] (het) c.[1468C > T] (het) |
p.(Glu81*) p.(Arg490Cys) |
Chinese | Proteinuria | FSGS | ND |
| 2–1 |
c.[448C > T] (het) c.[748G > C] (het) |
p.(Arg150*) p.(Asp250His) |
Chinese | SRNS | FSGS | ND | |
| 3–1 |
c.[532C > T] (het) c.[748G > C] (het) |
P.(Arg178Trp) p.(Asp250His) |
Chinese | SRNS |
Sclerosing Glomerulonep-hritis |
ND | |
| 4–1 | c.[737G > A] (homo) | p.(Ser246Asn) | Chinese | SRNS | FSGS | ND | |
| 5–1 | c.[737G > A](homo) | p.(Ser246Asn) | Chinese | Proteinuria | MsPGN | ND | |
| 6–1 | c.[748G > C](homo) | p.(Asp250His) | Chinese | NS | ND | ND | |
| 7–1 | c.[748G > C] (homo) | p.(Asp250His) | Chinese | SRNS | FSGS | ND | |
| 8–1 |
c.[748G > C] (het) c.[1093C > G] (het) |
p.(Asp250His) p.(Gln365Glu) |
Chinese | Proteinuria | FSGS | ND | |
| Feng C et al [23] (2017) | 1–1 |
c.[748G > C] (het) c.[532C > T] (het) |
p.(Asp250His) P.(Arg178Trp) |
Chinese | Proteinuria | ND | CoQ10 |
| 2–1 |
c.[625C > G] (het) c.[614C > T] (het) |
p.(Asp209His) p.(Ser205Asn) |
Chinese | SRNS | ND | PNL, tacrolimus, CoQ10 | |
| Song X et al [24] (2017) | 1–1 |
c.[737G > A] (het) c.[748G > C] (het) |
p.(Ser246Asn) p.(Asp250His) |
Chinese | Proteinuria | FSGS+GS | PNL, tacrolimus, ACEI,CoQ10 |
| 2–1 | c.[737G > A] (homo) | p.(Ser246Asn) | Chinese | SRNS | Global abandonment | PNL, HD, PD, CoQ10 | |
| 3–1 | c.[737G > A] (homo) | p.(Ser246Asn) | Chinese | SRNS | FSGS | PNL, PD, renal transplantation | |
| 4–1 | c.[748G > C] (homo) | p.(Asp250His) | Chinese | SRNS | MsPGN | PNL, tacrolimus,MMF, CoQ10 | |
| 4–2 | c.[748G > C] (homo) | p.(Asp250His) | Chinese | SRNS | EndPGN | PNL, HD, PD, CoQ10 | |
| 5–1 | c.[748G > C] (homo) | p.(Asp250His) | Chinese | Proteinuria | FSGS+GS | ACEI,CoQ10, PD | |
| 6–1 |
c.[551A > G] (het) c.[737G > A] (het) |
p.(Asp184Gly) p.(Ser246Asn) |
Chinese | Proteinuria | FSGS+GS | PNL, CsA, tacrolimus, RTX, CTX, PD, CoQ10 | |
| 7–1 | c.[737G > A] (homo) | p.(Ser246Asn) | Chinese | Proteinuria | FSGS | PNL, CoQ10 | |
| Park E et al [6] (2017) | 1–1 |
c.[449G > A] (het) c.[759C > A] (het) |
p.(Arg150Gln) p.(Asn253Lys) |
Korean | Proteinuria | FSGS | ND |
| 1–2 |
c.[449G > A] (het) c.[759C > A] (het) |
p.(Arg150Gln) p.(Asn253Lys) |
Korean | Proteinuria | FSGS | ND | |
| 2–1 |
c.[737G > A] (het) c.[759C > A] (het) |
p.(Ser246Asn) p.(Asn253Lys) |
Korean | Proteinuria | FSGS | ND | |
| 3–1 | c.[737G > A] (homo) | p.(Ser246Asn) | Korean | Proteinuria | FSGS | ND | |
| 4–1 |
c.[737G > A] (het) c.[1468C > T] (het) |
p.(Ser246Asn) p.(Arg490Cys) |
Korean | Proteinuria | FSGS | ND | |
| 5–1 | c.[737G > A] (homo) | p.(Ser246Asn) | Korean | Proteinuria | FSGS | CoQ10 | |
| Lolin K et al [25] (2017) | 1–1 |
c.[649G > A] c.[748G > T] |
p.(Ala217Thr) P.(Asp250Tyr) |
Belgian | Proteinuria | FSGS | CoQ10 |
| Yang J et al [16] (2018) | 1–1 |
c.[625C > G] (het) c.[918G > T] (het) |
p.(Asp209His) p.(Cys306X) |
Chinese | Proteinuria | FSGS | CoQ10 |
| Atmaca M et al [26] (2019) | 1–1, 1–2 | c.[1199dupA] (homo) | p.(His400Glnfs*11) | European | Proteinuria | ND | CoQ10 |
| 2–1 | c.[1199dupA] (homo) | p.(His400Glnfs*11) | European | Proteinuria | ND | CoQ10 | |
| 3–1 | c.[1199dupA] (homo) | p.(His400Glnfs*11) | European | Proteinuria | ND | CoQ10 | |
| 4–1 | c.[293 T > G] (homo) | p.(Leu98Arg) | European | Proteinuria | ND | ACEI, ARB, CoQ10 | |
| Yang Z et al [27] (2019) | 1–1 |
c.[748G > C] (het) c.1041G > T (het) |
p.(Asp250His) p.(Cys347*) |
Chinese | Proteinuria | MGA | ND |
ND No data or not do, GS Global glomerulosclerosis, het Heterozygous, homo Homozygous, PNL Prednisolone, CsA Cyclosporine A, CP-R Cyclophosphamide resistant, FSGS Focal segmental glomerulosclerosis, MsPGN Mesangial proliferative glomerulonephritis, EndPGN Endoproliferative glomerulonephritis, MGA Minor glomerular abnormalities
Primary coenzyme Q10 deficiency is considered as the only treatable mitochondrial disorder, since these patients can respond to the given oral coenzyme Q10 supplementation [28]. Early study considers that, oral coenzyme Q10 may stop the progression of encephalopathy, but it is not beneficial for the evolution of renal disease associated with this deficiency [29, 30]. Recently, Ashraf et al. [11] reported a SRNS patient with homozygous ADCK4 frameshift mutation who had partial remission following CoQ10 treatment. Korkmaz et al. [21] reported two patients with early stage ADCK4-GN who demonstrated improved proteinuria during the 6-week CoQ10 supplementation. In addition, Atmaca et al. [31] examined the efficacy of CoQ10 supplementation in treating eight patients with ADCK4-GN, and found that proteinuria was significantly improved, whereas eGFR was preserved. Feng et al. [23] reported two children with proteinuria renal disease related to ADCK4 mutation, of them, case 1 was a 9-month-girl with non-nephrotic range proteinuria who achieved full response to CoQ10 therapy, while case 2 was diagnosed with SRNS who showed the renal pathology of FSGS and had no response to CoQ10 supplementation. Another paper suggests that the early administration of CoQ10 is important for mitigating the renal symptoms of CoQ10 nephropathy [28]. Our patient received CoQ10 supplementation when he was 3 years old and the proteinuria gradually decreased by 52.5% during the 5-month follow-up period. Yet, such a follow-up period is still too short to evaluate the effects, which is one of the shortcomings in this paper. Nonetheless, in a long-term follow-up study that applies CoQ10 supplementation in patients with ADCK4 variants diagnosed during the asymptomatic period, it is discovered that, CoQ10 treatment is effective on reducing proteinuria, which seems to be renoprotective [26]. Combined with these previous reports and our data, it is implied that the early recognition of ADCK4 mutation and the early CoQ10 supplementation to patients are important for patients with full or partial response to CoQ10 supplementation and benign prognosis.
Notably, rapid progression to ESRD is common in most cases, even though in our case, the patient presented with mild phenotype at the time of diagnosis. Besides, renal biopsy and WES have greatly facilitated the early diagnosis, which can also avoid misdiagnosis and the use of toxic drugs. Early CoQ10 supplementation achieves positive effects, therefore, early diagnosis will help to identify children at the early disease stages who are eligible for accurate CoQ10 therapy with benign prognosis.
Acknowledgements
Our thanks should go to the patient, his family and the authors who participated in this study. At the same time, Dr. Zhang wants to express her appreciation to JJ Lin, for his songs have brought spiritual power in her hard time.
Abbreviations
- ADCK4
AarF domain-containing kinase 4
- ADCK4-GN
ADCK4-associated glomerulopathy
- MGA
Minor glomerular abnormalities
- WES
Whole exome sequencing
- CoQ10
Coenzyme Q
- LM
Light microscope
- EM
Electron microscope
- eGFR
Estimated glomerular filtration rate;
- SRNS
Steroid-resistant nephrotic syndrome
- FSGS
Focal segmental glomerulosclerosis
- LMWP
Low molecular weight proteinuria
- ACEI
Angiotensin converting-enzyme inhibitor
- ESRD
End-stage renal disease
- NGS
Next generation sequencing
Authors’ contributions
ZL collected the clinical information and wrote the manuscript. SBC was in charge of data collection and interpretation. ZY carried out genetic studies and evaluated the mutants based on expression and functional studies. ZSB and MQS reviewed the draft and made critical modifications. All authors had read and approved the final manuscript.
Funding
Not available.
Availability of data and materials
The datasets used and analyzed in this study are available from the corresponding author on reasonable request.
Ethics approval and consent to participate
This study was approved by the Ethics Committee of the First Hospital of Jilin University. The boy in this case report was 3 years old (under 18 years old) and his informed consent was written by his parents. All the informed consents were written in Chinese. WES is essential for diagnosis. Parents expressed full understanding and consent to be examined. This consent was verbal.
Consent for publication
The boy in this case report was 3 years old and the consent for publication was obtained from his parents. A copy of the written consent was available for the review by the editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Shu-bo Zhai, Email: jelly4sci@sina.com.
Li Zhang, Email: zhangli7year@sina.com.
Bai-chao Sun, Email: sunbaichao_11@163.com.
Yan Zhang, Email: zy1014@jlu.edu.cn.
Qing-shan Ma, Email: maqs@jlu.edu.cn.
References
- 1.Chang-Chien C, Chuang GT, Tsai IJ, Chiang BL, Yang YH. A large retrospective review of persistent proteinuria in children. J Formos Med Assoc. 2018;117(8):711–719. doi: 10.1016/j.jfma.2017.09.004. [DOI] [PubMed] [Google Scholar]
- 2.Leung AK, Wong AH, Barg SS. Proteinuria in children: evaluation and differential diagnosis. Am Fam Physician. 2017;95(4):248–254. [PubMed] [Google Scholar]
- 3.Warady BA, Abraham AG, Schwartz GJ, et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) cohort. Am J Kidney Dis. 2015;65(6):878–888. doi: 10.1053/j.ajkd.2015.01.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hildebrandt F. Genetics of kidney diseases. Semin Nephrol. 2016;36(6):472–474. doi: 10.1016/j.semnephrol.2016.09.011. [DOI] [PubMed] [Google Scholar]
- 5.Malaga-Dieguez L, Susztak K. ADCK4 “reenergizes” nephrotic syndrome. J Clin Invest. 2013;123(12):4996–4999. doi: 10.1172/JCI73168. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Park E, Kang HG, Choi YH, et al. Focal segmental glomerulosclerosis and medullary nephrocalcinosis in children with ADCK4 mutations. Pediatr Nephrol. 2017;32(9):1547–1554. doi: 10.1007/s00467-017-3657-9. [DOI] [PubMed] [Google Scholar]
- 7.Wang F, Zhang Y, Mao J, et al. Spectrum of mutations in Chinese children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2017;32(7):1181–1192. doi: 10.1007/s00467-017-3590-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Rao J, Liu X, Mao J, et al. Genetic spectrum of renal disease for 1001 Chinese children based on a multicenter registration system. Clin Genet. 2019;96(5):402–410. doi: 10.1111/cge.13606. [DOI] [PubMed] [Google Scholar]
- 9.Zhang H, Wang F, Liu X, Zhong X, Yao Y, Xiao H. Steroid-resistant nephrotic syndrome caused by co-inheritance of mutations at NPHS1 and ADCK4 genes in two Chinese siblings. Intractable Rare Dis Res. 2017;6(4):299–303. doi: 10.5582/irdr.2017.01037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Tranchant C, Anheim M. Movement disorders in mitochondrial diseases. Rev Neurol (Paris) 2016;172(8–9):524–529. doi: 10.1016/j.neurol.2016.07.003. [DOI] [PubMed] [Google Scholar]
- 11.Ashraf S, Gee HY, Woerner S, et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest. 2013;123(12):5179–5189. doi: 10.1172/JCI69000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Kakiuchi T, Ohtsuka Y, Sato T, et al. Association between Crohn's disease and AarF domain-containing kinase 4 glomerulopathy. Clin J Gastroenterol. 2019;12(3):263–268. doi: 10.1007/s12328-019-00937-3. [DOI] [PubMed] [Google Scholar]
- 13.Doimo M, Desbats MA, Cerqua C, Cassina M, Trevisson E, Salviati L. Genetics of coenzyme q10 deficiency. Mol Syndromol. 2014;5(3–4):156–162. doi: 10.1159/000362826. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Desbats MA, Lunardi G, Doimo M, Trevisson E, Salviati L. Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency. J Inherit Metab Dis. 2015;38(1):145–156. doi: 10.1007/s10545-014-9749-9. [DOI] [PubMed] [Google Scholar]
- 15.Acosta MJ, Vazquez Fonseca L, Desbats MA, et al. Coenzyme Q biosynthesis in health and disease. Biochim Biophys Acta. 2016;1857(8):1079–1085. doi: 10.1016/j.bbabio.2016.03.036. [DOI] [PubMed] [Google Scholar]
- 16.Yang J, Yang Y, Hu Z. A novel ADCK4 mutation in a Chinese family with ADCK4-associated glomerulopathy. Biochem Biophys Res Commun. 2018;506(3):444–449. doi: 10.1016/j.bbrc.2018.10.102. [DOI] [PubMed] [Google Scholar]
- 17.Vazquez Fonseca L, Doimo M, Calderan C, et al. Mutations in COQ8B (ADCK4) found in patients with steroid-resistant nephrotic syndrome alter COQ8B function. Hum Mutat. 2018;39(3):406–414. doi: 10.1002/humu.23376. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Antignac C. Genetic models: clues for understanding the pathogenesis of idiopathic nephrotic syndrome. J Clin Invest. 2002;109(4):447–449. doi: 10.1172/JCI15094. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Zhao F, Zhu JY, Richman A, et al. Mutations in NUP160 are implicated in steroid-resistant Nephrotic syndrome. J Am Soc Nephrol. 2019;30(5):840–853. doi: 10.1681/ASN.2018080786. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Preston R, Stuart HM, Lennon R. Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how? Pediatr Nephrol. 2019;34(2):195–210. doi: 10.1007/s00467-017-3838-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Korkmaz E, Lipska-Ziętkiewicz BS, Boyer O, et al. ADCK4-associated Glomerulopathy causes adolescence-onset FSGS. J Am Soc Nephrol. 2016;27(1):63–68. doi: 10.1681/ASN.2014121240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Li G, Sun L, Shen Q, et al. Mitochondrial nephropathy in two children and literature review. Chin J Evid Based Pediatr. 2015;10:426–433. [Google Scholar]
- 23.Feng C, Wang Q, Wang J, et al. Coenzyme Q10 supplementation therapy for 2 children with proteinuria renal disease and ADCK4 mutation: case reports and literature review. Medicine (Baltimore) 2017;96(47):e8880. doi: 10.1097/MD.0000000000008880. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Song X, Xu H, Shen Q, et al. Clinical and genetic chatacters of 8 Chinese children with ADCK4- associated glomerulopathy. Chin J Nephrol. 2017;33:22–29. [Google Scholar]
- 25.Lolin K, Chiodini BD, Hennaut E, Adams B, Dahan K, Ismaili K. Early-onset of ADCK4 glomerulopathy with renal failure: a case report. BMC Med Genet. 2017;18(1):28. doi: 10.1186/s12881-017-0392-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Atmaca M, Gülhan B, Atayar E, et al. Long-term follow-up results of patients with ADCK4 mutations who have been diagnosed in the asymptomatic period: effects of early initiation of CoQ10 supplementation. Turk J Pediatr. 2019;61(5):657–663. doi: 10.24953/turkjped.2019.05.003. [DOI] [PubMed] [Google Scholar]
- 27.Yang Z, Gu C, Zheng X, Tan H, Lu Y, Ma Y. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019;36(6):598–601. doi: 10.3760/cma.j.issn.1003-9406.2019.06.017. [DOI] [PubMed] [Google Scholar]
- 28.Montini G, Malaventura C, Salviati L. Early coenzyme Q10 supplementation in primary coenzyme Q10 deficiency. N Engl J Med. 2008;358(26):2849–2850. doi: 10.1056/NEJMc0800582. [DOI] [PubMed] [Google Scholar]
- 29.Salviati L, Sacconi S, Murer L, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology. 2005;65(4):606–608. doi: 10.1212/01.wnl.0000172859.55579.a7. [DOI] [PubMed] [Google Scholar]
- 30.Rötig A, Appelkvist EL, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet. 2000;356(9227):391–395. doi: 10.1016/S0140-6736(00)02531-9. [DOI] [PubMed] [Google Scholar]
- 31.Atmaca M, Gulhan B, Korkmaz E, et al. Follow-up results of patients with ADCK4 mutations and the efficacy of CoQ10 treatment. Pediatr Nephrol. 2017;32(8):1369–1375. doi: 10.1007/s00467-017-3634-3. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets used and analyzed in this study are available from the corresponding author on reasonable request.